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S U P P L E M E N T A R T I C L E
Pretransplant Evaluation for Infections
in Donors and Recipients of Solid Organs
Andreas Schaffner
Department of Internal Medicine, University Hospital, Zurich, Switzerland
The risk of infectious disease reactivation in recipients of and transmission by solid-organ transplants remains,
and thorough screening and testing of recipient and donor is especially important. In conceiving screening
strategies, it is crucial to consider the sensitivity and specificity of individual diagnostic tests in the context
of their use. Furthermore, recognition of special risks for infectious complications of transplantation will help
to guide preventive, diagnostic, and therapeutic steps in the control of infectious complications in individual
patients. The acceptability of risks for infectious complications after transplantation depends also on the
urgency of transplantation of a vital organ as well as the availability of organs. Although these principals are
well accepted, standards for the extent of screening and criteria for inappropriate donors and exclusion of
unfit recipients remain controversial to some extent.
It is universally accepted that donors and recipients of
solid organs should be screened for infections, to elim-
inate unsuitable donors and recipients who would not
appropriately gain from transplantation. Furthermore,
recognition of special risks for infectious complications
of transplantation will help to guide preventive, diag-
nostic, and therapeutic steps in the control of infectious
complications in individual patients. Although these
principles are well accepted, standards for the extent of
screening and criteria for inappropriate donors and ex-
clusion of unfit recipients remain controversial to some
extent.
Various factors affect the screening strategy in organ
donors (table 1) and recipients (table 2) and the de-
cision on when not to perform a transplantation. The
acceptability of risks for infectious complications after
transplantation depends also on the urgency of trans-
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plantation of a vital organ as well as the availability of
organs.
In conceiving screening strategies, it is also important
to consider the sensitivity and specificity of individual
diagnostic tests in the context of their use. In screening
donors, it might often be preferable to use a test with
a high sensitivity, in order to avoid an inadvertent trans-
mission by transplantation. On the other hand, a test
with a high specificity might be more appropriate in
recipients, in order not to dismiss the possibility of a
primary infection on the basis of false-positive test
results.
DONOR SCREENING
General measures. A complete medical history of the
donor should be obtained by the organization procur-
ing the organs, with a particular focus on vaccinations,
infections, and unusual exposures (residence in en-
demic areas, travel, drug use, risky sexual behavior, in-
carceration). Viruses, bacteria, fungi, parasites, and
prions have all been transmitted from the donor to the
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Table 1. Factors governing screening of solid-organ donors.
Agent
Prevalence
in donors
Screening
efficient Transmission rate
Potential
damage
Preventive/
therapeutic options
Cytomegalovirus 0.5 Yes 180% in R Low to high Both
HIV Lowa Yes 190% High Limited
Human T cell lymphotropic virus type 1 Low–15%a 50% false positive Not shown; very likely High Experimental
Toxoplasma gondii 10%–75% Yes Heart ∼50% in R Low to high Both
Epstein-Barr virus 190% Yes 180% in R None to high Experimental
Hepatitis B virus Lowa Yes High Low to high Limited
Hepatitis C virus 1%–7% Yes, false positive 50% or 100% None to high Limited
Syphilis Lowa Yes Not shown; likely ? to low Both
Mycobacterium tuberculosis Lowa No Shown Low to high Both
Prions Very lowa No ? High None
NOTE. R, seronegative recipient; ?, no data available.
a Low, !1%.
host with the transplant. Actual clinical infections should be
sought aggressively, including microbiologic documentation
and, where appropriate, drug-susceptibility testing. Geographic
diseases (e.g., endemic mycoses, schistosomiasis, malaria, and
babesiosis) require special attention. Donor infections do not
automatically preclude transplantation [1] but should be
treated adequately before and, in some instances, after trans-
plantation [2–4]. Of particular concern is the presence of in-
fection or colonization with multiresistant pathogens, partic-
ularly methicillin-resistant Staphylococcus aureus (MRSA) and
vancomycin-resistant enterococci. Blood cultures should be ob-
tained from cadaveric donors at the time of organ taking (B-
II) [5]. For a useful interpretation of serologic results, serum
samples should be obtained before mass transfusions of po-
tential organ donors, and the number of transfusions given
before collection of the samples should be recorded. It has been
advised to perform autopsies on all cadaveric donors, in order
to document occult infection in addition to neoplastic disease
(B-II) [6, 7].
HIV. Among the most detrimental infections transmitted
from the donor to the recipient is the HIV type-1 (HIV-1)
infection. The transmission rate is high, regardless of the trans-
planted organ. By serology, only 1 of 34 recipients of a kidney
from an HIV-infected donor remained seronegative 6 months
after transplantation. The 5-year survival was 50% for the 61
recipients of HIV-infected kidneys, compared with 85% in un-
infected patients, and 35% for 24 reported patients receiving
an HIV-infected liver, compared with 63% in the other recip-
ients [8]. Screening of donors with a highly sensitive assay for
the presence of HIV antibodies is therefore routine in all centers
and is part of all regulations on donor screening (A-II) [9, 10].
Several instances of HIV transmission by transplants from
individuals who had not yet seroconverted and were antibody-
negative in early primary infection have been reported [8].
Therefore, screening for HIV-1 p24 antigen has been proposed
in addition to testing for antibody to HIV-1/HIV-2 [11]. On
the basis of the available data, the panel recommends testing
for both antigen and antibody (A-II). The diagnostic window
can, however, be shortened by p24 antigen testing by only ∼6
days. PCR would further shorten this window by another 5
days [12]; however, at least for cadaveric donors of solid organs,
the time frame required for PCR frequently does not permit
application of this technology. Nevertheless, the panel proposes
to test donors for antibody, p24 antigen, and HIV RNA when-
ever possible (A-III). By applying multiple tests for HIV screen-
ing, the problem of false-positive results increases, which leads
to a waste of perfectly suitable organs. In an analysis of 500,000
blood donations tested for antibody and p24 antigen, the ma-
jority of patients testing positive for p24 antigen were shown
to be false-positive [13]. To supplement laboratory testing, the
Centers for Disease Control and Prevention guidelines [9] rec-
ommend use of the past history of donors to apprehend further
the risk of HIV infection escaping laboratory screening (risky
sexual behavior, hemophilia, incarceration). These recommen-
dations foresee the information for potential recipients of the
possibility of an increased risk of HIV transmission.
Cytomegalovirus (CMV). CMV has been shown to be
transmitted by all solid-organ transplants from seropositive do-
nors [14, 15]. The vast majority of seronegative (i.e., immu-
nologically naive) recipients will acquire CMV from kidneys,
hearts, lungs, pancreas, or small bowel, procured from sero-
positive donors, and are at high risk to develop CMV disease
within the first months after transplantation or to bear other
consequences of CMV infection. Superinfection by CMV from
the organ donor to seropositive recipients has been documented
by molecular methods [16, 17]. Serologic testing for CMV in-
fection, preferably by IgG ELISA, is regarded as mandatory by
all authorities (A-II). The ELISAs or latex agglutination tests
used are very sensitive but are hampered by a high rate of false-
positive test results, which are estimated to occur in 10%–15%
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Table 2. Factors governing screening of solid-organ recipients.
Agent
Prevalence
in recipients
Screening
efficient
R/ affects
susceptibility
Reactivation or
affecting prognosis
Preventive/
therapeutic options
Cytomegalovirus 0.5 Yes Yes Low to intermediate Both
HIV Lowa Yes No Intermediate Limited
Toxoplasma gondii 15%–70% Yes Yes ? to low Both
Hepatitis B virus Lowa Yes Yes Low to high Both
Hepatitis C virus Intermediate Yes Not documented Intermediate Limited
Epstein-Barr virus 190% Yes Yes None Experimental
Human T cell lymphotropic virus type I Low–15%a False positive ? ? to low Experimental
Mycobacterium tuberculosis Lowa No ? Low to intermediate Both
NOTE. R/, serostatus of recipient; ?, no data available.
a Low, !1%.
of cases [11]. Although, in terms of prevention, misclassifying
seronegative donors as positive might be preferable over the
opposite error, false-positive tests cause unnecessary costs and
toxicity of superfluous preventive therapy. The risk of donors
acquiring CMV by blood products shortly before organ pro-
curement has been regarded as small (!1%) [11]; however, anti-
CMV immunoglobulins passively transferred might taint test
results if blood samples are drawn after blood products are
given to organ donors. The use of IgM anti-CMV in donor
screening has been considered but is not advocated on the basis
of the little information gained and the high rate of false-
positive results (E-III) [11].
Epstein-Barr virus (EBV). Primary EBV infection through
infected organs or transmission of latently EBV-infected blood
donor lymphocytes to EBV-negative recipients increases their
risk of developing EBV-associated lymphoproliferative disease
manifold. Because of the high prevalence of latent EBV infec-
tion in the adult population with a pretest probability of a
positive test result for EBV IgG of 190%–95%, the increment
of information by EBV screening is small. The positive pre-
dictive value of anti–Epstein-Barr Virus Nuclear Antigen–1 IgG
testing is so high (99.8%) [18] that screening can be rec-
ommended (A-III).
Hepatitis B virus (HBV). HBV can be transmitted by all
solid-organ transplants, but the transmission rate depends on
the stage of HBV infection in the donor, the presence or absence
of viremia, and/or replication of virus in the liver and presum-
ably on the anti-HBs (antibodies to HB virus surface antigen)
immune status of the recipient. Several markers, which reflect
the stage and course of HBV infection, permit definition of the
risk of transmission. There is agreement that all donors should
be tested for HBs antigen (A-I) based on the observation that
HB surface antigen (HBs Ag)–positive donors regularly [19,
20], but not always [21], transmit the infection to the recipient.
Because anti-HB core antibody (HBc) might be the only marker
of early HBV infection or of a continuous circulation of HBV
DNA and/or of infective virus in the liver [22], and because
anti–HBc-positive donors cannot whereas HBs antigen-nega-
tive donors can transmit HBV, even with organs other than the
liver [23–25], anti-HBc antibody should be routinely tested in
all organ donors (A-I). Some experts also recommend the rou-
tine testing of anti-HBs antibody in order to supply further
information on the true nature of a positive anti-HBc test and
because of a reduced risk of transmission by extrahepatic organs
by HBs Ab–positive donors [11] (B-II). Others have found that,
regardless of the anti-HBs antibody status, kidneys from
anti–HBc IgG-positive, anti–HBc IgM-negative HBs anti-
gen–negative donors can safely be used in recipients with a
history of HBs vaccination (even if they are anti-HBs–antibody
negative) or HBV infection [24] (B-II). It is intriguing, however,
that these authors have noted that, even in the absence of
clinically overt HBV infection, several of their patients sero-
converted with respect to their anti-HBs status. If time permits
PCR for HBV, DNA should be considered in unclear situations
[26].
Hepatitis C virus (HCV). HCV is transmitted by 50%–
100% of organs from anti–HBC-positive donors to HBC-neg-
ative recipients [27–31]. HCV infection usually takes a chronic
indolent and slowly progressive course, with cirrhosis and liver
failure or liver cancer not developing before 5–20 years after
infection [32]. Therefore, the ultimate consequences of trans-
plantation acquired HCV might not yet be evident because the
first documented transplantation-associated HCV infection an-
tedates this study by only a few years [33]. Nevertheless, it has
been found in a cohort of 29 anti-HCV–negative recipients that
received organs from HCV-positive (by first-generation ELISA)
donors that graft survival and mortality were not worse after
a follow up of 5–9 years than in a control group receiving
HCV-negative organs [27]. The risk for chronic liver disease
was, however, 4.4 times higher after transplantation of HCV-
positive organs, and 1 death occurring among the 29 recipients
was attributed to HCV hepatitis and rejection of the trans-
planted liver. Another caveat stems from the observation by
the authors that patients with preexisting HCV infection, an-
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Table 3. Criteria for rejecting or accepting solid-organ transplantation in infected cadaveric donors and/or recipients.
Infection Donor status
Recipient
status
Recommendation
regarding transplantation Special aspects
HIV Positive Negative Reject
Irrelevant Positive Experimental ? D/R
Cytomegalovirus Positive Positive Accept Antiviral strategy
Positive Accept
Toxoplasma gondii Positive Negative Accept Prophylaxis after heart and
liver transplantation
Hepatitis B virus HB surface antigen–positive Negative Reject
Positive Experimental Accept for lifesaving
transplantation
Anti-HB core–positive, HB
surface–antigen–negative
Negative Accept extrahepatic
organs
Consider liver in desperate
situations
Hepatitis C virus Positive Negative Decision depends on
urgency of SOT and age
of recipient
Accept only for urgent
SOT and/or elderly
recipients
Positive Positive Accept
Human T-cell lymphotropic
virus type 1/type2
Positive Negative ? Accept only for urgent
SOT
No transmission docu-
mented by SOT, but
very likely
Epstein-Barr virus Positive Negative Accept ? Future antiviral strategy
NOTE. HB, hepatitis B; HC, hepatitis C; SOT, solid-organ transplantation; ?, no data available.
tedating transplantation by many months and years, had a
worse prognosis, presumably because of the longer duration of
their hepatitis. In similar studies based on a more specific,
second-generation ELISA for donor screening, albeit with
shorter observation periods, virtually all seronegative recipients
were infected through HCV-positive organs [28, 30] and ∼50%
developed liver disease [31]. In 1 study, 1 of 15 patients with
transplantation-acquired HCV infection died from liver failure
55 months after renal transplantation [31]. Because of an absent
or delayed antibody response to HCV, diagnosis of transplant-
transmitted infection cannot be based solely on antibody testing
but frequently requires assays for HCV RNA [28, 30, 31, 34].
On the basis of the transmissibility and the consequences of
HCV infection, all donors should be screened for anti-HCV
antibodies. Although a second-generation ELISA is more spe-
cific (98%) than its predecessor, its positive predictive value
nevertheless remains low in donor populations with a low prev-
alence of HCV (55.1% in a large US collaborative study [29]),
which results in an unnecessary waste of organs. HCV RNA
assays are better predictors of transplant-transmitted, HCV-
associated liver disease, but a negative PCR does not exclude
HCV transmission [29], and, again, PCR is not practical for
screening cadaveric donors. The panel recommends screening
of all donors by (a second-generation) ELISA (A-I).
Toxoplasma gondii. T. gondii can be transmitted by solid-
organ transplants to the recipient, the result being potentially
fatal infections in seronegative recipients. Because of the pro-
pensity of Toxoplasma to persist in its encysted form in the
heart muscle, recipients of heart transplants are particularly
prone to transplant-acquired toxoplasmosis [35, 36], but fatal
cases have also been observed after renal [37, 38] or liver trans-
plantation [39]. Without prophylaxis, ∼50% of seronegative
heart recipients, 20% of liver recipients, and !1% of kidney
recipients acquire toxoplasmosis through the organ of a sero-
positive donor. With a prevalence of T. gondii in the general
population of 10%–75%, depending on the geographic area, a
mismatch in the serostatus of donor and recipient is common.
Prophylaxis for Pneumocystic carinii with cotrimoxazole ap-
pears to have eliminated much of the toxoplasmosis problem
[40, 41]. Because not all patients receive or tolerate cotrimox-
azole or another effective prophylactic regimen (i.e., pyrime-
thamine), all donors should be screened for the presence of
Toxoplasma antibody (A-II).
Human T cell lymphotropic virus type 1 (HTLV-1)/HTLV-
2. HTLV-1 virus infection is endemic in Japan, the Caribbean,
Australia, and parts of Africa, with a seroprevalence of
15%–18% [42]. Most infections remain clinically quiet, but
some infections have been associated with adult T cell leukemia
or chronic neurologic diseases. HTLV-2 infection has not been
definitely associated with any disease. Screening tests usually
detect cross-reacting antibodies to HTLV-1/2. Seroprevalence
in Europe and the United States in blood donors is !0.5%. A
French study found in potential organ donors a frequency of
Western blot–confirmed HTLV-1/2 positivity of 0.47% [43].
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Four of 6 positive screening results were considered false-pos-
itive. HTLV-1 and HTLV-2 are transmitted sexually, by breast-
feeding, and by cellular components of blood products (T cells).
Transmission through solid-organ transplantation has not been
documented and reported, but concern arises from reports of
HTLV-1–associated myelopathy in a heart transplant patient
acquiring the retrovirus from a blood transfusion [44] and a
report of a T cell leukemia/lymphoma in an HTLV-1–positive
renal transplant patient [45]. For these reasons, HTLV-1/2
screening is performed in many countries not only in blood
but also in solid-organ donors, and in some countries screening
is mandatory. Most experts of the panel recommend HTLV-1/
2 screening (C-III).
RECIPIENT SCREENING
The aims of screening the potential recipient of a solid-organ
transplant are 4-fold:
(1) To determine the immune status of the recipient against
common pathogens that can be transmitted by transplants. This
is because established immunity against pathogens such as
CMV, T. gondii, and possibly HBV protects the recipient from
severe sequelae of a primoinfection with these agents.
(2) To permit the allocation of organs from donors infected
with a certain pathogen to recipients who are already carriers
of this agent, such as HCV infection.
(3) To recognize and possibly treat infections that can be
expected to exacerbate or reactivate after immunosuppression
such as tuberculosis, the endemic dimorphic mycoses such as
coccidioidomycosis and histoplasmosis, or strongyloidiasis.
(4) To avoid transplantation in patients with a poor prognosis
after transplantation, such as HIV infection or colonization
with certain panresistant bacteria.
A clinical and radiological workup for the detection of occult
or latent infection should, in addition to a thorough history
and physical examination, include in all patients a chest film
in 2 planes for detection of infiltrates and residues of chronic
infections such as tuberculosis, coccidioidomycosis, or histo-
plasmosis (B-III), a tuberculin skin test (C-III), and stool ex-
aminations for parasites (C-III).
Despite being performed often in transplant recipients, there
is no evidence that radiographic evaluation for dental foci and
their eradication is necessary (D-II). A case-control study in
cases with untreated dental foci had results comparable to those
without dental foci [46].
There is no evidence for the necessity of routine radiographic
evaluation of the paranasal sinuses in solid-organ transplant
(SOT) recipients (E-III), except in patients with cystic fibrosis
awaiting a lung transplant and those with clinical sign or symp-
toms of sinusitis. In these cases direct sagittal computed to-
mography imaging is the procedure of choice (B-II).
SUMMARY
On the basis of this concept, the panel recommends screening
for anti–HIV-1/HIV-2 (A-III), anti-CMV IgG (A-II), anti-Tox-
oplasma IgG (A-II), anti-Epstein-Barr Virus Nuclear Antigen
IgG (A-II), HBs antigen, anti-HCV antibodies (A-II), anti-HBs
antibodies, anti-HBc antibodies (A-III), and, at least in he-
modialysis patients, HCV PCR (A-II). The reasoning of these
recommendations is given in table 2 and the Donor Screening
section.
Criteria formulated by the consensus panel for accepting or
rejecting transplantation on the basis of infections in donors
and recipients are summarized in table 3. Not included in the
table are guidelines for transplantation of organs from donors
that have infections with bacteria that can easily controlled with
antibiotics, such as meningitis caused by Neisseria meningitis
or penicillin-susceptible pneumococci [1]; however, infections
with multiresistant microorganisms such as MRSA, vanco-
mycin-resistant enterococci, or Burkholderia cepacia might be
an insurmountable obstacle to transplantation. Transplantation
of organs from patients with invasive fungal infections might
similarly pose a problem.
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